Development Of Radiation Necrosis In Metastatic Melanoma Following Stereotactic Radiosurgery With Concurrent Systemic Therapy

Abstract

0.02] and 6-months (48% superior [95% CI 7.4-89.5%, p Z 0.02] compared to those commencing >4 weeks post SRS however lesion regression velocity was comparable by 9-and 12-months. A 1mm increase in maximal lesion diameter was associated with a 1.5% (95% CI 0.04-2.9, p Z 0.04) and 2% (95% CI 0.4-3.7%, p Z 0.016) greater reduction in volume at 3-and 6-months. 5% of patients experienced symptomatic radionecrosis (RN). 19% had non-RT grade 3 or higher toxicity. Conclusion: This study demonstrates a significantly greater volumetric regression with concurrent immunotherapy and SRS in MBM in the initial 6 months post SRS. Combined modality treatment offers excellent local control with low RN specific toxicity.